DK4121007T3 - Højkoncentrationsformuleringer afanti-amyloid-betapeptid-protofibril-antistoffer og fremgangsmåder til anvendelse deraf - Google Patents
Højkoncentrationsformuleringer afanti-amyloid-betapeptid-protofibril-antistoffer og fremgangsmåder til anvendelse derafInfo
- Publication number
- DK4121007T3 DK4121007T3 DK21722538.2T DK21722538T DK4121007T3 DK 4121007 T3 DK4121007 T3 DK 4121007T3 DK 21722538 T DK21722538 T DK 21722538T DK 4121007 T3 DK4121007 T3 DK 4121007T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- high concentration
- concentration formulations
- betapeptide
- amyloid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992746P | 2020-03-20 | 2020-03-20 | |
| US202063027263P | 2020-05-19 | 2020-05-19 | |
| PCT/IB2021/000155 WO2021186245A1 (en) | 2020-03-20 | 2021-03-19 | HIGH CONCENTRATION ANTI-Aß PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4121007T3 true DK4121007T3 (da) | 2025-09-22 |
Family
ID=75746958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21722538.2T DK4121007T3 (da) | 2020-03-20 | 2021-03-19 | Højkoncentrationsformuleringer afanti-amyloid-betapeptid-protofibril-antistoffer og fremgangsmåder til anvendelse deraf |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20230183328A1 (da) |
| EP (2) | EP4252777A3 (da) |
| JP (2) | JP7689141B2 (da) |
| KR (1) | KR20220156534A (da) |
| CN (1) | CN115315251A (da) |
| AU (1) | AU2021238951A1 (da) |
| BR (1) | BR112022018766A2 (da) |
| CA (1) | CA3174778A1 (da) |
| CL (2) | CL2022002517A1 (da) |
| CO (1) | CO2022012916A2 (da) |
| DK (1) | DK4121007T3 (da) |
| ES (1) | ES3041762T3 (da) |
| FI (1) | FI4121007T3 (da) |
| HR (1) | HRP20251087T1 (da) |
| HU (1) | HUE072937T2 (da) |
| IL (2) | IL326613A (da) |
| LT (1) | LT4121007T (da) |
| MA (1) | MA59082B1 (da) |
| MD (1) | MD4121007T2 (da) |
| MX (1) | MX2022011101A (da) |
| PH (1) | PH12022552172A1 (da) |
| PL (1) | PL4121007T3 (da) |
| PT (1) | PT4121007T (da) |
| RS (1) | RS67249B1 (da) |
| SI (1) | SI4121007T1 (da) |
| SM (1) | SMT202500350T1 (da) |
| WO (1) | WO2021186245A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022020680A1 (en) | 2020-07-23 | 2022-01-27 | Othair Prothena Limited | Anti-abeta antibodies |
| AU2022307687A1 (en) | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| JP2025506389A (ja) | 2022-02-02 | 2025-03-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ｐ－タウ１８１レベルを使用した治療方法 |
| CN120202218A (zh) | 2022-11-28 | 2025-06-24 | 卫材R&D管理有限公司 | 使用tau PET水平的治疗方法 |
| WO2024254542A1 (en) | 2023-06-09 | 2024-12-12 | Eisai R&D Management Co., Ltd. | Methods of treatment using an anti-abeta protofibril antibody |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| AU2018321335B2 (en) | 2017-08-22 | 2025-08-14 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| CA3107370A1 (en) * | 2018-07-24 | 2020-01-30 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
-
2021
- 2021-03-19 HU HUE21722538A patent/HUE072937T2/hu unknown
- 2021-03-19 CA CA3174778A patent/CA3174778A1/en active Pending
- 2021-03-19 LT LTEPPCT/IB2021/000155T patent/LT4121007T/lt unknown
- 2021-03-19 BR BR112022018766A patent/BR112022018766A2/pt unknown
- 2021-03-19 IL IL326613A patent/IL326613A/en unknown
- 2021-03-19 JP JP2022556091A patent/JP7689141B2/ja active Active
- 2021-03-19 IL IL295383A patent/IL295383B1/en unknown
- 2021-03-19 EP EP23179487.6A patent/EP4252777A3/en active Pending
- 2021-03-19 HR HRP20251087TT patent/HRP20251087T1/hr unknown
- 2021-03-19 WO PCT/IB2021/000155 patent/WO2021186245A1/en not_active Ceased
- 2021-03-19 MX MX2022011101A patent/MX2022011101A/es unknown
- 2021-03-19 US US17/906,660 patent/US20230183328A1/en active Pending
- 2021-03-19 ES ES21722538T patent/ES3041762T3/es active Active
- 2021-03-19 EP EP21722538.2A patent/EP4121007B1/en active Active
- 2021-03-19 FI FIEP21722538.2T patent/FI4121007T3/fi active
- 2021-03-19 MA MA59082A patent/MA59082B1/fr unknown
- 2021-03-19 PH PH1/2022/552172A patent/PH12022552172A1/en unknown
- 2021-03-19 DK DK21722538.2T patent/DK4121007T3/da active
- 2021-03-19 KR KR1020227030919A patent/KR20220156534A/ko active Pending
- 2021-03-19 MD MDE20230104T patent/MD4121007T2/ro unknown
- 2021-03-19 AU AU2021238951A patent/AU2021238951A1/en active Pending
- 2021-03-19 SM SM20250350T patent/SMT202500350T1/it unknown
- 2021-03-19 CN CN202180019180.6A patent/CN115315251A/zh active Pending
- 2021-03-19 SI SI202130347T patent/SI4121007T1/sl unknown
- 2021-03-19 PL PL21722538.2T patent/PL4121007T3/pl unknown
- 2021-03-19 PT PT217225382T patent/PT4121007T/pt unknown
- 2021-03-19 RS RS20250922A patent/RS67249B1/sr unknown
-
2022
- 2022-09-12 CO CONC2022/0012916A patent/CO2022012916A2/es unknown
- 2022-09-14 CL CL2022002517A patent/CL2022002517A1/es unknown
-
2024
- 2024-11-08 CL CL2024003428A patent/CL2024003428A1/es unknown
-
2025
- 2025-04-10 JP JP2025064827A patent/JP2025111516A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4267105T3 (da) | Antistofsammensætninger og fremgangsmåder til anvendelse deraf | |
| DK4232463T3 (da) | Interleukin-2-fc-fusionsproteiner og fremgangsmåder til anvendelses | |
| DK3618928T5 (da) | Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK4216753T3 (da) | Lyshærdbare kunstige negle, fremgangsmåder til fremstilling og fremgangsmåder til anvendelse deraf | |
| DK4161935T3 (da) | Brm-målrettende forbindelser og tilhørende anvendelsesmetoder | |
| DK3963021T3 (da) | Stabiliserede fluorolefinsammensætninger og fremgangsmåder til anvendelse deraf | |
| IL284661A (en) | Pcsk9 inhibitors and methods of use thereof | |
| DK4011908T5 (da) | Ultralangtidsvirkende insulin-FC-fusionsproteiner og fremgangsmåder til anvendelse deraf | |
| IL326613A (en) | High concentration anti-aß protofibril antibody formulations and methods of use thereof | |
| EP3934669A4 (en) | Prostate-specific membrane antigen cars and methods of use thereof | |
| DK3774789T3 (da) | BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse | |
| DK3761980T3 (da) | Aminosyreforbindelser og fremgangsmåder til anvendelse | |
| DK3752251T3 (da) | Arginasehæmmere og fremgangsmåder til anvendelse deraf | |
| DK3852533T3 (da) | Pyridazinoner og fremgangsmåder til anvendelse deraf | |
| DK3743447T3 (da) | B7-H4-antistoffer og fremgangsmåder til anvendelse deraf | |
| KR20240101677A9 (ko) | Dickkopf-1 변이체 항체 및 사용 방법 | |
| IL311301A (en) | Anti-siglec-6 antibodies and methods of use thereof | |
| IL282424A (en) | Alk2 antibodies and methods of use thereof | |
| LT4200018T (lt) | Anti-par-2 antikūnai ir jų panaudojimo būdas | |
| DK3743088T3 (da) | IL-22 Fc-sammensætninger og fremgangsmåder til anvendelse | |
| DK3840837T3 (da) | Arginasehæmmere og fremgangsmåder til anvendelse deraf | |
| IL299700A (en) | Kcnt1 inhibitors and methods of use | |
| IL286485A (en) | Pi4-kinase inhibitors and methods of using the same | |
| IL309571A (en) | Cdk2 inhibitors and methods of using the same | |
| IL298668B1 (en) | Anti-CD200R1 antibodies and methods of using them |